



Financial Tear Sheet

Corporate Profile

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA[®]ER, NUCYNTA[®], Gralise[®], Cambia[®], Lazanda[®] and Zipsor[®]. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential. Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform[®], that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed's products:

NUCYNTA[®] ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

NUCYNTA[®] (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

Gralise[®] (gabapentin), a once-daily product for the management of postherpetic neuralgia,

Cambia[®] (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

Lazanda[®] (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

Zipsor[®] (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for [Gralise](#) and the black box warnings for [NUCYNTA ER](#), [NUCYNTA](#), [Cambia](#), [Lazanda](#) and [Zipsor](#).

Stock Performance

DEPO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$6.16
Change (%)	0.00 (0.00%)
Volume	683,725
52 Week Low	\$4.31
Market Cap	\$388,162,858
Rolling EPS	-1.83
PE Ratio	N/A
Shares Outstanding	63,013,451



Recent Headlines

11/07/17

Depomed Announces Third Quarter 2017 Financial Results

11/07/17

Depomed and Slán Medicinal Holdings Ltd Announce Strategic Asset Transactions

10/31/17

Depomed to Report Third Quarter 2017 Financial Results on Tuesday, November 7, 2017

Upcoming Events

There are currently no events scheduled.

Ownership Summary

TOP HOLDERS

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	8,944,996	14.2	603,122	09/30/17
Senvest Management, LLC	5,605,105	8.9	0	09/30/17
Starboard Value LP	5,295,270	8.4	0	09/30/17
Armistice Capital LLC	4,652,000	7.4	2,220,000	09/30/17
The Vanguard Group, Inc.	3,934,881	6.2	-398,226	09/30/17
Dimensional Fund Advisors, L.P.	2,321,109	3.7	14,791	09/30/17
State Street Global Advisors (US)	2,290,198	3.6	-44,780	09/30/17
Millennium Management LLC	1,294,715	2.1	888,586	09/30/17
Morgan Stanley & Co. LLC	1,220,679	1.9	296,650	09/30/17
Renaissance Technologies LLC	1,019,200	1.6	820,762	09/30/17

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed